Drugs / MTP-101C
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07490054 | Sep 2025 → Sep 2027 expected | heart failure | Melana Yuzefpolskaya, MD | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07017946 | Jan → Nov 2026 expected | amyotrophic lateral sclerosis | Duke University | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07528690 | Oct 2026 → Oct 2030 expected | cirrhosis of liver, hepatic encephalopathy | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06499896 | Jan 2025 → Sep 2027 expected | dermatitis, undetermined colitis | Diwakar Davar | Recruiting | No outcome recorded |
| Phase 2 | NCT06631586 | Jan 2025 → Jun 2029 expected | Crohn disease | University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTP-101C | “MTP-101-C is manufactured using cGMP protocols in the Molecular and Cellular Therapeutics (MCT) facility at the University of Minnesota.” NCT07528690 ↗5“Compound MTP-101C, which is a standardized form of MTT targeting delivery into the distal intestine, will be used.” NCT07528690 ↗ |
| Modality | Other / unclassified | “full spectrum, healthy donor fecal microbiota product” NCT06499896 ↗ |
| Route | Oral | “Participants will then ingest 2 capsules of MTP-101C daily for 3 days, then 1 capsule of MTP-101C daily for 8 weeks.” NCT07017946 ↗ |